Efficacy and Safety of DEH113 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea

Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexFemale
Age16-35
SponsorEMS

About this trial

The purpose of this study if to evaluate the efficacy and safety of DEH113 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patient has given written informed consent to participate in the study prior to admission to the study;

Female patients aged between 16 and 35 years old, inclusive;

History of regular menstrual cycles, occuring between every 21 to 35 days;

Clinical history compatible with the diagnosis of primary dysmenorrhea;

Disqualifiers

Diagnosis of secondary dysmenorrhea;

History of non-response to treatment with non-steroidal anti-inflammatory drugs (NSAIDs) to relieve menstrual cramps;

Onset of primary dysmenorrhea after starting to use oral contraceptives;

Use of oral contraceptives for < 4 months prior to study selection;

Trial design

Design model

Crossover

Treatments tested in this trial

  • DEH113

    Drug

    Tablets

  • Placebo Comparator

    Drug

    Tablets

Treatment groups

78 Participants
are divided into 2 treatment groups
Group A: DEH113Experimental treatment 1 intervention
Group B: ControlPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Sum of Total Pain Relief (TOTPAR) over 0-6 hours post-dose

Pain relief will be evaluated considering the Sum of Total Pain Relief (TOTPAR) over 0-6 hours post-dose. Pain relief will be evaluate using a Categorical Pain Relief Rating Scale (0 = No relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief).

Time frame
6 hours post-dose

Secondary outcomes

1

Sum of Total Pain Relief (TOTPAR) over 0-4 and 0-8 hours post-dose

Pain relief will be evaluated considering the Sum of Total Pain Relief (TOTPAR) over 0-4 and 0-8 hours post-dose. Pain relief will be evaluate using a Categorical Pain Relief Rating Scale (0 = No relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief).

Time frame
4 and 8 hours post-dose
2

Sum of Pain Intensity Difference (SPID) over 4, 6 and 8 hours post-dose.

Sum of Pain Intensity Difference (SPID) over 4, 6 and 8 hours post-dose. The pain intensity will be assessed using a Categorical 4-point scale (0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain).

Time frame
4, 6 and 8 hours post-dose
3

Use of rescue medication

Proportion of participants who used rescue medication in the first 24 hours after the first drug intake, amount of rescue medication used in the first 24 hours after the first drug intake, and time elapsed between the last drug intake and the first administration of rescue medication.

Time frame
24 hours post-dose
4

Number of additional drug intake

Number of additional drug intake during the 24 hours after the first drug intake

Time frame
24 hours post-dose

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: